• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » First successful lab-grown vaginas herald disruptive innovation on the horizon

First successful lab-grown vaginas herald disruptive innovation on the horizon

April 11, 2014 By Arezu Sarvestani

First successful lab-grown vaginas herald disruptive innovation on the horizon

A team of researchers successfully implanted 4 young women with laboratory grown vaginas for the first time, representing an important breakthrough in regenerative medicine.

The women, aged 13-18 at the time of implantation, were born with Mayer-Rokitansky-Küster-Hauser syndrome, a rare genetic disease that left them with underdeveloped or absent vaginal organs. They had no sexual function and were unable to menstruate.

Now, 8 years after the first operation, all 4 women reported healthy sexual function and 2 have uteruses and could potentially get pregnant, the Wall Street Journal reported.

There’s a long way to go before lab-grown organs are available on the healthcare market, but success in the new studies may spur more research.

"This pilot study is the first to demonstrate that vaginal organs can be constructed in the lab and used successfully in humans," lead researcher Dr. Anthony Atala of Forest Baptist Medical Center’s Institute for Regenerative Medicine said in prepared remarks. "This may represent a new option for patients who require vaginal reconstructive surgeries. In addition, this study is one more example of how regenerative medicine strategies can be applied to a variety of tissues and organs."

Follow-up exams and surveys found that the engineered tissue was "indistinguishable" from native cells. The patients reported normal sexual function, including desire and pain-free intercourse.

The scientists engineered the organs by growing the patent’s own cells on a scaffold made of tissue from pig’s intestine. The cultivated tissue was shaped into a vagina and implanted at the Metropolitan Autonomous University in Mexico City.

The patients’ bodies gradually embraced the new tissue and new nerves and blood vessels formed around it.

The study was reported this week in the journal The Lancet, alongside another report of scientists implanting patients with engineered nostrils that operate as well as natural organs.

"These two Lancet studies show that those who practice conventional tissue reconstruction and organ transplantation, and the health-care and commercial industries which support them, should finally be taking the quirky minnows of tissue engineering quite seriously," Martin Birchall and Alexander Seifalian wrote in a commentary accompanying the Lancet publication. "Disruptive innovation might be nigh.

Filed Under: News Well, Regenerative Medicine, Research & Development, Women's Health Tagged With: Clinical Trials, Tissue Regeneration, Wake Forest University

More recent news

  • Zimmer Biomet to expand robotic suite with Monogram acquisition
  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy